Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 528
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.

Detailed description:
This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligilibilty criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week Treatment period. There will be a 7-day Follow-up period after the treatment period.

Arms:
arm 1: Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA) arm 2: Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA

Interventions: intervention 1: Fluticasone Furoate 100mcg/Vilanterol 25mcg intervention 2: Fluticaosne Propionate 500mcg/Salmeterol 50mcg
Intervention descriptions: intervention 1: Inhalation Powder intervention 2: Inhalation Powder

Protocol document: